Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

Summary

The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilisate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with residual changes in the lungs after COVID-19 infection

Timeline

Start

2022-04-08

Primary completion

2023-12-31

Completion

2023-12-31

Outcome

Missed primary endpoint

paper The pre-specified primary endpoint (Δ ppFVC at Day 71) was negative (+0.30%, p = 0.817). PMID 42261259 ↗

Publications

• Avdeev SN, Ignatova GL, Drapkina OM, Popova VB, Melnikova EV, Chudinovskikh TI, Ryabova OV, Egorova NV, Rubanik TV, Shvarts YG, Polyakova SA, Antonova AV, Zubkov DA, Khmelevskii MS, Khomyakova NF, Tsyferov MA, Hardman TC, Tikhonov AA. Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID19: a multicenter, randomized, double-blind, placebo-controlled study. Expert Rev Respir Med. 2026 Jun 10:1-11. doi: 10.1080/17476348.2026.2684077. Online ahead of print.

Drugs

Indications